BARDA Announces $500 Million Project NextGen Funding for Novel COVID-19 Vaccines

BARDA is investing in Phase 2b clinical trials for intranasal and oral COVID-19 vaccines, aiming to provide needle-free, mucosal immune response-inducing options.

The Biomedical Advanced Research and Development Authority (BARDA) is announcing up to $500 million in Project NextGen funding to “plan and execute multiple Phase 2b clinical trials evaluating novel vaccines administered as a nasal spray or as a pill to protect against symptomatic COVID-19.” HHS's website has the release.

The three companies receiving money from the project are Vaxart ($453 million), Castlevax ($34 million), and Cyanvac ($40 million). Vaxart is developing an oral pill vaccine candidate, and the latter two companies are developing an intranasal vaccine candidate.

Currently approved COVID-19 vaccines, administered intramuscularly, are extremely effective but “limited in their capacity to induce a robust immune response in mucosal areas such as the mouth, nose, and gut, where the SARS-CoV-2 virus first enters the body. Successful development of intranasal and oral vaccines would provide safe, effective, needle-free vaccines that are easier-to-administer options with the potential to improve vaccine access.”

Each of the clinical trials will recruit 10,000 volunteers, and the investigational vaccines’ efficacy will be compared to that of FDA-licensed vaccines.

About the Author

Matt MacKenzie

Matt MacKenzie

Associate Editor

Matt MacKenzie is Senior Staff Writer and Associate Editor of Healthcare Purchasing News (HPN), where he leads daily news coverage and contributes in-depth features on healthcare supply chain, sterile processing, infection prevention and clinical operations. Through industry reporting and expert interviews, he examines the trends, technologies and operational challenges shaping healthcare purchasing and patient care. 

Sign up for our eNewsletters
Get the latest news and updates